IRONWOOD PHARMACEUTICALS INC (IRWD)

Company Profile

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 267 full-time employees. The company went IPO on 2010-02-03. The company is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. The company is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. The company is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. The company is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.

Company Info

IRONWOOD PHARMACEUTICALS INC

100 Summer Street, Suite 2300

Boston MASSACHUSETTS 02110

P: 16176217722

CEO: Mark Mallon

Employees: 267

Website: https://www.ironwoodpharma.com/